Antares Pharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Antares Pharma Inc. - overview
Established
1979
Location
Ewing, NJ, US
Primary Industry
Pharmaceuticals
About
Antares Pharma Inc. is a biopharmaceutical company specializing in innovative drug delivery systems to improve patient experiences and outcomes. The firm is dedicated to developing solutions for the administration of biologics and other therapeutics. Founded in 1979 in Ewing, US, Antares Pharma Inc.
focuses on enhancing drug delivery methods. The company's operational strategy has remained consistent, emphasizing the development of advanced drug delivery technologies. The current leadership includes Bob Apple and Venus Melendez, who guide the company in its mission. Antares has not been reported as a subsidiary or involved in mergers, maintaining its independent status since inception.
The firm has engaged in 1 deal as of February 1, 2007, which signifies its ongoing efforts to advance its product offerings. Antares Pharma Inc. specializes in innovative drug delivery technologies aimed at improving patient experiences. The company’s core offerings include the development of platforms that facilitate the subcutaneous delivery of biologics, enhancing treatment protocols for various therapeutic agents such as monoclonal antibodies.
Antares’s technologies are utilized by biotechnology and pharmaceutical companies globally, ensuring efficient drug administration and better health outcomes for patients across North America, Europe, and Asia. In 2021, Antares Pharma Inc. reported a revenue of USD 183. 98 mn with an EBITDA of USD 69.
83 mn. The company's financial model is centered around partnerships and licensing agreements, generating revenue through collaborations that leverage its advanced drug delivery solutions. Antares Pharma Inc. aims to expand its product portfolio with upcoming innovations in drug delivery technologies.
The company is focusing on penetrating new markets in Europe and Asia, looking to establish a more significant presence by 2023. Recent funding will support the development and commercialization of new delivery systems, ensuring that the firm can meet the increasing demands of the biopharmaceutical industry. The most recent deal on February 1, 2007, further underscores the company's commitment to growth and innovation.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.antarespharma.com
Total Amount Raised
Subscriber access only
Antares Pharma Inc. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 22,575,578 | 20,618,500 | 26,501,665 | 45,658,100 | 52,222,046 | 54,515,000 | 63,554,000 | - | - | - |
| % Revenue Growth (YoY) | - | (8.7%) | 28.5% | 72.3% | 14.4% | 4.4% | 16.6% | - | - | - |
| EBITDA (USD) | (11,220,471) | (20,081,980) | (33,869,042) | (18,881,818) | (22,243,553) | (14,347,000) | (1,377,000) | - | - | - |
| Operating Income (USD) | (11,451,499) | (20,850,317) | (35,113,295) | (20,461,979) | (24,116,460) | (16,451,000) | (4,101,000) | - | - | - |
| Operating Margin | (50.7%) | (101.1%) | (132.5%) | (44.8%) | (46.2%) | (30.2%) | (6.5%) | - | - | - |
| % EBITDA Margin | (49.7%) | (97.4%) | (127.8%) | (41.4%) | (42.6%) | (26.3%) | (2.2%) | - | - | - |
| NET Income (USD) | (11,427,450) | (20,506,776) | (35,151,715) | (20,658,846) | (24,338,804) | (16,743,000) | (6,515,000) | - | - | - |
| % Net Margin | (50.6%) | (99.5%) | (132.6%) | (45.2%) | (46.6%) | (30.7%) | (10.3%) | - | - | - |
Antares Pharma Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Antares Pharma Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.